Clinical Trial Update: Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for epcoritamab in newly diagnosed marginal zone lymphoma, currently recruiting across MZL subtypes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue
• Marginal Zone Lymphoma
• Nodal Marginal Zone Lymphoma
• Splenic Marginal Zone Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Izidore Lossos, MD | Conditions: Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Status: RECRUITING